{"id":"idarubicine-plus-cytarabine-regimen","safety":{"commonSideEffects":[{"rate":"80-95","effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":"40-60","effect":"Mucositis"},{"rate":"50-70","effect":"Nausea and vomiting"},{"rate":"30-50","effect":"Infection"},{"rate":"5-15","effect":"Cardiotoxicity"},{"rate":"10-20","effect":"Hepatotoxicity"},{"rate":"5-15","effect":"Neurotoxicity (cytarabine syndrome)"}]},"_chembl":{"chemblId":"CHEMBL2447907","moleculeType":"Unknown","molecularWeight":"1365.63"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Idarubicin is a topoisomerase II inhibitor that intercalates into DNA and prevents strand religation, causing double-strand breaks. Cytarabine is a nucleoside analog that is phosphorylated intracellularly and incorporated into DNA, inhibiting DNA polymerase and blocking DNA synthesis. The combination exploits complementary mechanisms to maximize cytotoxicity against rapidly dividing leukemic blasts.","oneSentence":"Idarubicin intercalates into DNA and inhibits topoisomerase II, while cytarabine inhibits DNA synthesis, together inducing apoptosis in leukemic cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:15:25.876Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML), newly diagnosed or relapsed/refractory"}]},"trialDetails":[{"nctId":"NCT06744504","phase":"PHASE3","title":"Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-01-10","conditions":"AML, RUNX1-RUNX1T1 Fusion Protein Expression","enrollment":300},{"nctId":"NCT07407140","phase":"PHASE3","title":"VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-30","conditions":"AML, Adult","enrollment":300},{"nctId":"NCT07486479","phase":"PHASE3","title":"Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-03-10","conditions":"Acute Myeloid Leukemia (AML)","enrollment":204},{"nctId":"NCT06928376","phase":"PHASE2","title":"A Multicenter RCT of \"3+7\" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2024-04-18","conditions":"Acute Myeloid Leukemia, First Line Therapy","enrollment":160},{"nctId":"NCT05453903","phase":"PHASE1","title":"A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-10-04","conditions":"Leukemia, Myeloid, Acute","enrollment":196},{"nctId":"NCT07132684","phase":"PHASE3","title":"Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-08-31","conditions":"AML, Adult","enrollment":240},{"nctId":"NCT06226571","phase":"PHASE1","title":"A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias","status":"RECRUITING","sponsor":"Syndax Pharmaceuticals","startDate":"2024-05-21","conditions":"Acute Myeloid Leukemias","enrollment":76},{"nctId":"NCT03926624","phase":"PHASE3","title":"Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage","status":"TERMINATED","sponsor":"Delta-Fly Pharma, Inc.","startDate":"2019-11-22","conditions":"Leukemia, Myeloid, Acute","enrollment":167},{"nctId":"NCT06068621","phase":"PHASE2","title":"Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2023-03-01","conditions":"Acute Myeloid Leukemia","enrollment":200},{"nctId":"NCT07297173","phase":"PHASE1","title":"Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia","status":"RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2025-12-01","conditions":"Relapsed Leukemia, Refractory Leukemia","enrollment":5},{"nctId":"NCT06001788","phase":"PHASE1","title":"Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Kura Oncology, Inc.","startDate":"2024-02-22","conditions":"AML, AML With Mutated NPM1, Hematologic Malignancy","enrollment":171},{"nctId":"NCT00534469","phase":"PHASE2","title":"Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2000-02-08","conditions":"Leukemia","enrollment":60},{"nctId":"NCT06451861","phase":"PHASE2","title":"Randomized Study of ABC-14 Regimen Compared With \"3+7\" Standard Induction Therapy or AB-14 for ND AML","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2024-08-21","conditions":"Acute Myeloid Leukemia","enrollment":240},{"nctId":"NCT07059975","phase":"EARLY_PHASE1","title":"UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML","status":"RECRUITING","sponsor":"Joanna Yi","startDate":"2025-10-22","conditions":"Acute Myeloid Leukemia, Pediatric AML","enrollment":36},{"nctId":"NCT06387069","phase":"PHASE3","title":"A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Hutchmed","startDate":"2024-04-26","conditions":"Acute Myeloid Leukemia","enrollment":316},{"nctId":"NCT07108530","phase":"PHASE2","title":"Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-06","conditions":"Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT07059156","phase":"PHASE2, PHASE3","title":"Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-06-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":50},{"nctId":"NCT07028073","phase":"PHASE1, PHASE2","title":"A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-05-15","conditions":"Acute Myeloid Leukemia With T(8;21)(Q22;Q22), Acute Myeloid Leukemia With T(16;16)(P13;Q22), KIT Gene Mutation","enrollment":78},{"nctId":"NCT02937662","phase":"PHASE2","title":"Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2016-10","conditions":"Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT06744556","phase":"PHASE2","title":"HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-01-21","conditions":"AML","enrollment":60},{"nctId":"NCT06066242","phase":"NA","title":"Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemotherapy","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-10-01","conditions":"Acute Myeloid Leukemia","enrollment":90},{"nctId":"NCT02688140","phase":"PHASE3","title":"Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia","status":"COMPLETED","sponsor":"Technische Universität Dresden","startDate":"2016-06","conditions":"Acute Promyelocytic Leukemia","enrollment":135},{"nctId":"NCT06810791","phase":"PHASE3","title":"HVA vs IA/DA or VA in the Treatment of ND HR-AML","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-01-01","conditions":"Newly Diagnosed Acute Myeloid Leukemia With High Risk","enrollment":876},{"nctId":"NCT06529250","phase":"NA","title":"Intermediate-dose HAD Regimen for CEBPA Double-mutated AML","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-08-13","conditions":"AML","enrollment":148},{"nctId":"NCT06643962","phase":"NA","title":"Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy","status":"RECRUITING","sponsor":"Affiliated Hospital of Nantong University","startDate":"2024-10-31","conditions":"Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute","enrollment":83},{"nctId":"NCT06652685","phase":"PHASE2","title":"Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-10-30","conditions":"Acute Myeloid Leukemia (AML)","enrollment":218},{"nctId":"NCT05557110","phase":"PHASE2","title":"Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL","status":"COMPLETED","sponsor":"Chen Suning","startDate":"2022-09-08","conditions":"B Acute Lymphoblastic Leukemia","enrollment":35},{"nctId":"NCT02907359","phase":"PHASE3","title":"Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2017-01-13","conditions":"Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic","enrollment":417},{"nctId":"NCT06221683","phase":"PHASE2","title":"Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML","status":"RECRUITING","sponsor":"Children's Hospital of Soochow University","startDate":"2024-01-01","conditions":"AML, Childhood, Acute Myeloid Leukemia","enrollment":500},{"nctId":"NCT06316960","phase":"PHASE2","title":"Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation","status":"RECRUITING","sponsor":"Children's Hospital of Soochow University","startDate":"2024-03-01","conditions":"AML, Childhood, Relapse/Recurrence, Refractory AML","enrollment":50},{"nctId":"NCT02323022","phase":"PHASE3","title":"Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2014-12","conditions":"Acute Myeloid Leukemia","enrollment":618},{"nctId":"NCT06497062","phase":"PHASE2","title":"Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2024-09-04","conditions":"Acute Myeloid Leukemia","enrollment":47},{"nctId":"NCT06301425","phase":"NA","title":"MRD Response-adapted Allo-HSCT for Adverse-risk AML","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-05-24","conditions":"Acute Myeloid Leukemia","enrollment":178},{"nctId":"NCT02013167","phase":"PHASE3","title":"Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)","status":"TERMINATED","sponsor":"Amgen","startDate":"2014-01-03","conditions":"Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia","enrollment":405},{"nctId":"NCT06232694","phase":"NA","title":"Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-01-01","conditions":"Acute Myeloid Leukemia","enrollment":54},{"nctId":"NCT02665065","phase":"PHASE3","title":"Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actinium Pharmaceuticals","startDate":"2016-06","conditions":"Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute","enrollment":153},{"nctId":"NCT01154439","phase":"PHASE1","title":"Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2010-10","conditions":"Leukemia","enrollment":11},{"nctId":"NCT04248595","phase":"PHASE2","title":"Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML","status":"UNKNOWN","sponsor":"Ge Zheng","startDate":"2019-12-01","conditions":"Acute Myeloid Leukemia","enrollment":100},{"nctId":"NCT05518383","phase":"PHASE4","title":"B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021","status":"RECRUITING","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2022-05-25","conditions":"Non-hodgkin Lymphoma,B Cell, Burkitt Lymphoma, Primary Mediastinal Lymphoma","enrollment":300},{"nctId":"NCT03173612","phase":"NA","title":"The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2016-08","conditions":"Acute Myeloid Leukemia","enrollment":132},{"nctId":"NCT05053425","phase":"NA","title":"Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML","status":"UNKNOWN","sponsor":"LanZhou University","startDate":"2021-10-20","conditions":"Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT02665143","phase":"PHASE2","title":"A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Yale University","startDate":"2016-07-21","conditions":"Relapsed/Refractory Acute Myeloid Leukemia","enrollment":25},{"nctId":"NCT03985007","phase":"PHASE2","title":"CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2018-01-01","conditions":"Acute Myeloid Leukemia, Relapsed, Adult","enrollment":40},{"nctId":"NCT04112589","phase":"PHASE1, PHASE2","title":"A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment","status":"UNKNOWN","sponsor":"PETHEMA Foundation","startDate":"2019-12-26","conditions":"Acute Myeloid Leukemia","enrollment":63},{"nctId":"NCT00003405","phase":"PHASE2","title":"Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"1998-04","conditions":"Leukemia","enrollment":""},{"nctId":"NCT03257241","phase":"PHASE3","title":"A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old","status":"UNKNOWN","sponsor":"Polish Adult Leukemia Group","startDate":"2017-07-03","conditions":"Acute Myeloid Leukemia","enrollment":582},{"nctId":"NCT02440568","phase":"PHASE1, PHASE2","title":"AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients","status":"TERMINATED","sponsor":"University of Illinois at Chicago","startDate":"2015-06-05","conditions":"Acute Myeloid Leukemia","enrollment":22},{"nctId":"NCT03250338","phase":"PHASE3","title":"Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML","status":"UNKNOWN","sponsor":"Arog Pharmaceuticals, Inc.","startDate":"2018-06-05","conditions":"Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations","enrollment":322},{"nctId":"NCT04541277","phase":"PHASE2","title":"Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2020-09-01","conditions":"Acute Myeloid Leukemia, in Relapsed or Refractory, Acute Myeloid Leukemia, Elderly, Unfit, Acute Myeloid Leukemia With Positive Minimal Residual Disease","enrollment":55},{"nctId":"NCT03558607","phase":"PHASE1, PHASE2","title":"The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2018-05-17","conditions":"Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Disorder","enrollment":17},{"nctId":"NCT03390387","phase":"NA","title":"Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)","status":"UNKNOWN","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2015-11","conditions":"Childhood Acute Lymphoblastic Leukemia","enrollment":4000},{"nctId":"NCT04216771","phase":"PHASE2, PHASE3","title":"Comparing the Consolidation Regimens of IDA With Intermediate-dose Cytarabine Versus Intermediate-dose Cytarabine Alone for Elderly AML Patients","status":"UNKNOWN","sponsor":"Fujian Medical University","startDate":"2020-01","conditions":"AML in Remission","enrollment":320},{"nctId":"NCT00071799","phase":"PHASE3","title":"A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care","status":"COMPLETED","sponsor":"Celgene","startDate":"2003-11-01","conditions":"Myelodysplastic Syndromes","enrollment":358},{"nctId":"NCT04087967","phase":"PHASE3","title":"Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2019-04-01","conditions":"Acute Myeloid Leukemia, Induction Chemotherapy","enrollment":162},{"nctId":"NCT03446638","phase":"NA","title":"iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes","status":"WITHDRAWN","sponsor":"University of Florida","startDate":"2019-05","conditions":"Myelodysplastic Syndromes","enrollment":""},{"nctId":"NCT02306291","phase":"PHASE1, PHASE2","title":"Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML","status":"COMPLETED","sponsor":"GlycoMimetics Incorporated","startDate":"2015-03","conditions":"Leukemia, Myeloid, Acute","enrollment":91},{"nctId":"NCT01496547","phase":"PHASE2","title":"Sequential Intensive Chemotherapy Followed by RIC for Refractory and Relapse AML","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2011-01","conditions":"Acute Leukemia","enrollment":47},{"nctId":"NCT00002835","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"1995-10-30","conditions":"Lymphoma","enrollment":116},{"nctId":"NCT00002565","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"1994-05-25","conditions":"Lymphoma","enrollment":61},{"nctId":"NCT00422591","phase":"PHASE2","title":"Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-12","conditions":"Leukemia, Acute Myeloid Leukemia, AML","enrollment":175},{"nctId":"NCT03564704","phase":"PHASE2, PHASE3","title":"Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2016-02-14","conditions":"Leukemia, Leukemia, Acute, Adult Lymphoblastic Lymphoma","enrollment":80},{"nctId":"NCT03553238","phase":"PHASE2, PHASE3","title":"Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2016-02-14","conditions":"Leukemia, Acute, Leukemia, T Cell, Leukemia, Lymphoblastic","enrollment":70},{"nctId":"NCT02527174","phase":"PHASE1","title":"A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia","status":"WITHDRAWN","sponsor":"University of Alberta","startDate":"2016-11","conditions":"Leukemia, Myeloid, Acute, Leukemia, Monocytic, Acute, Leukemia, Myelomonocytic, Acute","enrollment":""},{"nctId":"NCT02844530","phase":"PHASE2","title":"Study Evaluating the Efficacy of 90Yttrium-epratuzumab in Adults With CD22+ Relapsed/Refractory B-ALL","status":"WITHDRAWN","sponsor":"Nantes University Hospital","startDate":"","conditions":"CD22+ Relapsed/Refractory B-ALL","enrollment":""},{"nctId":"NCT00495287","phase":"PHASE3","title":"A Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult Acute Myelogenous Leukemia (AML)","status":"COMPLETED","sponsor":"Northern Italy Leukemia Group","startDate":"2006-11","conditions":"Acute Myelogenous Leukemia","enrollment":573},{"nctId":"NCT00317408","phase":"NA","title":"Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma","status":"UNKNOWN","sponsor":"European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma","startDate":"2004-04","conditions":"Lymphoma","enrollment":96},{"nctId":"NCT01889407","phase":"","title":"Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2013-08","conditions":"Acute Myeloid Leukemia","enrollment":94},{"nctId":"NCT01990807","phase":"PHASE4","title":"Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2012-10","conditions":"Childhood Acute Lymphoblastic Leukemia, Philadelphia Chromosome, Ph^1^, Absent, B-cell Childhood Acute Lymphoblastic Leukemia","enrollment":20},{"nctId":"NCT00003602","phase":"PHASE3","title":"Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Riverside Haematology Group","startDate":"1998-03","conditions":"Leukemia, Myelodysplastic Syndromes","enrollment":400},{"nctId":"NCT00838240","phase":"PHASE1, PHASE2","title":"Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia","status":"UNKNOWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2008-11","conditions":"Leukemia, Myelodysplastic Syndromes","enrollment":114},{"nctId":"NCT01018069","phase":"PHASE2","title":"AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen","status":"TERMINATED","sponsor":"Aegera Therapeutics","startDate":"2009-11","conditions":"Leukemia","enrollment":60},{"nctId":"NCT01145846","phase":"PHASE3","title":"Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML)","status":"UNKNOWN","sponsor":"Cooperative Study Group A for Hematology","startDate":"2010-05","conditions":"Acute Myelogenous Leukemia","enrollment":316},{"nctId":"NCT01039363","phase":"PHASE2","title":"Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"","conditions":"Acute Myeloid Leukemia","enrollment":27},{"nctId":"NCT00925873","phase":"PHASE3","title":"GOELAMS SA4 Study: the Role of Fludarabine in the Treatment of Acute Myeloid Leukemia in the Elderly","status":"COMPLETED","sponsor":"French Innovative Leukemia Organisation","startDate":"1996-06","conditions":"Acute Myeloid Leukemia","enrollment":303},{"nctId":"NCT00700544","phase":"PHASE3","title":"Treatment Outcome in Elderly Patients","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2002-06","conditions":"AML, Elderly Patients","enrollment":330}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Idarubicine plus Cytarabine regimen","genericName":"Idarubicine plus Cytarabine regimen","companyName":"The First Affiliated Hospital of Soochow University","companyId":"the-first-affiliated-hospital-of-soochow-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Idarubicin intercalates into DNA and inhibits topoisomerase II, while cytarabine inhibits DNA synthesis, together inducing apoptosis in leukemic cells. Used for Acute myeloid leukemia (AML), newly diagnosed or relapsed/refractory.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}